Abstract: Disclosed are methods and systems and computer program products for determining DPB1 expression without the need for rs9277534 (3? UTR) sequence data. Such methods are useful in assessing HLA sequencing submitted to or already in donor databases for matches that will reduce the risk of hematopoietic transplant rejection (i.e., graft vs. host disease).

Abstract: Disclosed are methods and systems for the detection of variants of the SARS-CoV-2 virus that cause COVID-19. For example, disclosed are methods for identifying and/or tracking variants of SARS-CoV-2 comprising: (a) identifying a sample from a subject as positive for SARS-CoV-2 nucleic acid and/or antibodies to SARS-CoV-2; (b) generating a sample-specific SARS-CoV-2 nucleic acid from the sample; (c) performing nucleic acid sequencing on the sample-specific SARS-CoV-2 nucleic acid; and(d) determining whether the nucleic acid sequence comprises a SARS-CoV-2 variant sequence. Also disclosed are systems for performing any portion of the disclosed methods and computer-program products tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to perform any of the steps of the disclosed methods or run any portion of the disclosed systems.